Wednesday, March 17, 2021
In an appeal from a final rejection of a pending application, the US Court of Appeals for the Federal Circuit held that claims directed to methods for determining “haplotype phase” were correctly rejected under 35 USC § 101 as subject matter ineligible.
In Re Board of Trustees of The Leland Stanford Junior University, Case No. 20-1012 (Fed. Cir. Mar. 11, 2021) (Reyna, J.)
Haplotype phase is a scientific way of describing the methodology of determining from which parent a particular allele (or gene) is inherited. The representative claim involved (i) receiving allele data, (ii) receiving pedigree data, (iii) determining an inheritance state based on the allele data, (iv) receiving transition probability data; (v) receiving linkage disequilibrium data and then- determining a haplotype phase based on the pedigree data, the inheritance state for the information described in the allele data, the transition probability data and the population l
To embed, copy and paste the code into your website or blog:
The Federal Circuit affirmed a decision by the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB) rejecting claims for failure to satisfy the subject matter eligibility standard under 35 U.S.C. § 101, in
ex parte examination of claims to methods and related computing systems for genetic haplotyping in
In re Board of Trustees of the Leland Stanford Junior University.
The claimed method is recited in representative claim 1:
1. A method for resolving haplotype phase, comprising:
receiving allele data describing allele information regarding genotypes for a family comprising at least a mother, a father, and at least two children of the mother and the father, where the genotypes for the family contain single nucleotide variants and storing the allele data on a computer system comprising a processor and a memory;
Will There Be a Legislative Push to Reform Patent Eligibility Requirements During the Biden Administration? | Kilpatrick Townsend & Stockton LLP jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
To embed, copy and paste the code into your website or blog:
C. R. Bard Inc. and Bard Peripheral Vascular, Inc. (collectively, Bard), and AngioDynamics, Inc., manufactured vascular access ports that were inserted under a patient’s skin to enable medical providers to insert fluid into the patient’s veins without having to initiate a new intravenous line. The Food and Drug Administration (FDA) warned medical providers not to use vascular access ports for power injection unless the ports were labeled for such use.
1
Bard sold vascular ports that could be used for power injection, even though they had not been approved for such use by the FDA. Bard then developed detectible information that would dependably indicate the power injection function after the implanting of the port, using a radiographic marker with the letters “CT” etched in titanium foil. Bard included other identifiers that could be felt through the skin, as well as labeling on the packaging of the device. Bard r
Following last week's post on this blog (AI Patent Trends in the U.S. Patent Office: Is the U.S. Losing Its Lead?), we look deeper into the filing data of AI applications to better understand how.